Indication
Leber Congenital Amaurosis
3 clinical trials
3 products
Product
AAV2-hRPE65v2Clinical trial
A Long-Term Follow-Up Study in Subjects Who Received an Adenovirus-Associated Viral Vector Serotype 2 Containing the Human RPE65 Gene (AAV2-hRPE65v2, Voretigene Neparvovec-rzyl) Administered Via Subretinal InjectionStatus: Active (not recruiting), Estimated PCD: 2030-03-01
Clinical trial
A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]Status: Active (not recruiting), Estimated PCD: 2015-07-01
Product
AAV OPTIRPE65Clinical trial
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)Status: Completed, Estimated PCD: 2023-07-01